MedTrace Logo

Gamma-linolenic Acid Supplementation Study

NCT04481724 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2024-04-24

No results posted yet for this study

Summary

Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain. This study aims to understand the effect of gamma-linolenic acid (GLA) supplementation on weight loss maintenance in Virta Health patients.

Conditions

  • Weight Trajectory

Interventions

DIETARY_SUPPLEMENT

gamma-linolenic acid

3 capsules per day of GLA for 24 months

DIETARY_SUPPLEMENT

placebo

3 capsules per day of placebo for 24 months

Sponsors & Collaborators

  • Virta Health

    lead INDUSTRY

Principal Investigators

  • Shaminie Athinarayanan, PhD · Virta Health

  • Rebecca Adams, PhD · Virta Health

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-22
Primary Completion
2023-02-13
Completion
2023-09-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04481724 on ClinicalTrials.gov